ABSTRACT Neisseria gonorrhoeae is one of the leading antimicrobial resistance threats worldwide. This study determined the MICs of closthioamide to be 0.008 to 0.5 mg/liter for clinical N. gonorrhoeae strains and related species. Cross-resistance with existing antimicrobial resistance was not detected, indicating that closthioamide could be used to treat drug-resistant N. gonorrhoeae.
CTA synthesis. Closthioamide was synthesized according to the route described by Hertweck and coworkers (9, 10) . The core of CTA was synthesized by two consecutive peptide couplings and deprotections onto a 1,3-diaminopropane core with an N-protected beta-alanine, followed by a third peptide coupling to install the aromatic benzoic acid end caps. Thionation with Lawesson's reagent and deprotection under highly acidic conditions yielded CTA in five longest linear steps.
All of the reagents involved in the synthesis of CTA were obtained from SigmaAldrich, with the exception of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), which was obtained from Manchester Organics. All of the reaction solvents used for the synthesis were anhydrous and of the highest grade from Sigma-Aldrich. All of the routine solvents for workup and purification were obtained from VWR. The closthioamide stock solution was prepared at 100 mg/liter in 100% ethanol.
Statistical analysis. MIC 50 and MIC 90 were calculated with MIC data from clinical gonococcal strains only. The correlation between MICs for CTA and those for other antibiotics was determined with a Spearman's rank correlation test using STATA 14.2. The correlation coefficient was calculated using MIC data from clinical and reference gonococcal strains.
CTA susceptibility and cross-resistance to existing antimicrobials. The CTA MICs for the 149 clinical strains ranged between 0.008 mg/liter and 0.25 mg/liter (Table S1 ). The numbers of isolates with MICs of 0.008 mg/liter, 0.015 mg/liter, 0.031 mg/liter, 0.063 mg/liter, 0.125 mg/liter, and 0.25 mg/liter were one (1%), six (4%), 14 (9%), 53 (36%), 72 (48%), and three (2%), respectively ( ( Fig. 2) . The numbers of isolates for each combination of CTA and ciprofloxacin MICs are shown in Table 2 . MICs for azithromycin had the highest correlation with CTA MICs with an R 2 0.48. The imminent threat of untreatable gonorrhea is a global problem that urgently requires the development of new antimicrobial agents. In this study, the novel antimicrobial CTA inhibited the growth of 146/149 (98%) clinical gonococcal strains at Յ0.125 mg/liter, suggesting the use of a low concentration for a therapeutic dose would reduce any potential toxicity. Importantly, isolates resistant to ciprofloxacin and the first-line therapeutic agents ceftriaxone and azithromycin are as susceptible to CTA as strains sensitive to these antibiotics, suggesting CTA could be effective clinically against MDR N. gonorrhoeae strains. Closthioamide activity against N. gonorrhoeae is comparable to its activity against other AMR organisms (7).
The CTA mode of action has been linked to DNA gyrase, which is also a target for fluoroquinolones, suggesting the potential for cross-resistance with antibiotics such as ciprofloxacin. However, the analysis of the clinical isolates demonstrated no correlation between MICs of the two antibiotics. This is also supported by a study by Chiriac et al., Total  1  5  14  51  64  3  1  139 who found no cross-resistances between the two antimicrobials, although they did not examine N. gonorrhoeae (7) . This suggests that the active site for CTA may be elsewhere in the quinolone resistance-determining region (QRDR). Interestingly, the two N. perflava strains had the highest CTA MICs (Ͼ1 mg/liter), and the basis of this relative resistance requires further research to understand the specific resistance mechanisms.
In conclusion, CTA has high anti-gonococcal activity in vitro, even for multidrugresistant isolates, but further studies to evaluate the clinical potential of this antimicrobial are urgently required in light of the public health threat that gonorrhea poses.
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